1. Survival at 30 days
   
   
2. Survival at 1 year.

Secondary Endpoints
The secondary endpoints of this trial are:

1. Incidence of cardiac arrest, (including the following rhythms: VF or VT requiring defibrillation or cardioversion, asystole, PEA) or mortality from the time of presentation through the index hospitalization.
   
   
2. Composite of hospitalization for HF or death within 30 days and within1 year of enrollment.
   
   
3. Composite of hospitalization for cardiac cause of hospitalization or death within 30 days and within 1 year of enrollment.
   
   
4. Incidence of AMI as assessed by biomarker and ECG evidence of myocardial necrosis within the first 24 hours of enrollment.
   
   
5. Composite of in-hospital cardiac arrest (including the following rhythms: VF or VT requiring defibrillation or cardioversion, asystole, PEA), hospitalization for HF, or mortality within 1 year of enrollment.
   
   
6. Assessment of biologic markers (free fatty acids (FFAs) and n-3 polyunsaturated FFAs) at initial, 6 and 12 hours post-enrollment and cardiac electrical stability (T wave alternans, ventricular arrhythmias, and heart rate variability) by Holter recording for 12 hours after the initiation of the study drug infusion (Biological Mechanism Component).
   
   
7. Assessment of LV infarct size and function by Tc99m-sestamibi single photon emission computed tomography (SPECT) myocardial perfusion imaging at 30 days post-enrollment (Biological Mechanism Component).